You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,486,947


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,486,947
Title:Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H.sub.3-receptor ligands
Abstract: The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H.sub.3-receptors of histamine.
Inventor(s): Schwartz; Jean-Charles (Paris, FR), Lecomte; Jeanne-Marie (Paris, FR)
Assignee: Bioprojet (Paris, FR)
Application Number:11/909,778
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,486,947
Patent Claims: 1. A method for treating excessive daytime sleepiness comprising administering to a patient in need thereof a compound of formula (IIa): ##STR00065## wherein: R.sup.1 and R.sup.2 form together with the nitrogen atom to which they are attached a saturated nitrogen-containing ring ##STR00066## with m ranging from 2 to 8, or R.sup.a-b being independently a hydrogen atom or a linear or branched alkyl group containing 1 to 6 carbon atoms, and the chain A.sup.II selected from an unbranched alkyl group --(CH.sub.2).sub.nII-- where n.sub.II is 3 ; the group X'' is --O--; the chain B.sup.II is an unbranched alkyl comprising 3 carbon atoms; and the group Y.sup.II represents a phenyl group, unsubstituted or mono- or polysubstituted with one or more identical or different substituents selected from halogen atoms, OCF.sub.3, CHO, CF.sub.3, SO.sub.2N(alkyl).sub.2, NO.sub.2, S(aryl), SCH.sub.2(phenyl), an unbranched or branched alkene, an unbranched or branched alkyne optionally substituted with a trialkylsilyl radical, --O (alkyl), --O(aryl), --CH.sub.2CN, a ketone, an aldehyde, a sulphone, an acetal, an alcohol, a linear or branched alkyl group containing 1 to 6 carbon atoms, --CH.dbd.CH--CHO, --C(alkyl)=N--OH, --C(alkyl)=N--O(alkyl), --CH.dbd.NOH, --CH.dbd.NO(alkyl), --C(alkyl)=NH--NH--CONH.sub.2, an O-phenyl or --OCH.sub.2(phenyl) group, --C(cycloalkyl)=NOH, --C(cycloalkyl)=N--O(alkyl); or its pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereoisomers or enantiomers, wherein said patient is suffering from Parkinson's disease, narcolepsy, or sleep apnea.

2. The method according to claim 1 wherein --NR.sup.1R.sup.2 is a saturated nitrogen-containing ring: ##STR00067## R.sup.a and m being as defined in claim 1.

3. The method according to claim 1, wherein m is 4 or 5.

4. The method according to claim 1, wherein --NR.sup.1R.sup.2 is selected from the group consisting in piperidyl, pyrrolidinyl.

5. The method according to claim 1, wherein R.sup.a is a hydrogen atom.

6. The method according to claim 1, wherein the nitrogen-containing ring i) is one of mono- and di-substituted.

7. The method according to claim 1 , wherein the nitrogen-containing ring i) is mono-substituted with an alkyl group.

8. The method according to claim 1, wherein the nitrogen-containing ring is mono-substituted with a methyl group.

9. The method according to claim 1, wherein the substituent(s) is(are) in beta-position with respect to the nitrogen atom.

10. The method according to claim 1, wherein Y.sup.II represents a phenyl group at least mono-substituted with a halogen atom, keto-substituent which may include a linear or branched chain aliphatic ketone comprising from 1 to 8 carbon atoms and optionally bearing a hydroxyl group, a cycloalkylketone, an arylalkylketone or arylalkenylketone in which the aryl group is optionally substituted, or a heteroaryl ketone.

11. The method according to claim 1, wherein Y.sup.II is a phenyl group at least mono-substituted with a halogen atom, --CHO, a ketone, an aldehyde, --CH.dbd.CH--CHO, --C(alkyl)=N--OH, --C(alkyl)=N--O(alkyl), --CH.dbd.NO(alkyl), -(cycloalkyl)=NOH, --C(cycloalkyl)=N--O (alkyl).

12. The method according to claim 1, wherein the compound is selected from: -3-Phenylpropyl 3-piperidinopropyl ether -3-(4-Chlorophenyl)propyl 3 -piperidinopropyl ether -3-Phenylpropyl 3-(4.about.methylpiperidino)propyl ether -3-Phenylpropyl 3-(3,5-cis-dimethylpiperidino)propyl ether -3-Phenylpropyl 3-(3,5-trans-dimethylpiperidino)propyl ether -3-Phenylpropyl 3-(3-methylpiperidino)propyl ether -3-Phenylpropyl 3-pyrrolidinopropyl ether -3-(4-Chlorophenyl)propyl 3-(4-methylpiperidino)propyl ether -3-(4-Chlorophenyl) propyl 3-(3,5-cis-dimethyl piperidino)propyl ether -3-(4-Chlorophenyl) propyl 3-(3,5-trans-dimethyl piperidino)propyl ether, or its pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereoisomers or enantiomers.

13. The method according to claim 1, wherein the compound is selected from 3-(4-chlorophenyl)propyl-3-piperidino- propylether, or its pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of this compound or its optical isomers, racemates, diastereoisomers or enantiomers.

14. The method according to claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt and said salt is chosen from the group consisting in hydrochloride, hydrobromide, hydrogen maleate or hydrogen oxalate.

15. A method according to claim 1 further comprising administering a ligand of the H3 receptor in combination with a medicament for treating of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies and/or vascular dementia, respectively.

16. The method according to claim 1 in which said treatment is intended for treating symptoms of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies and/or vascular dementia.

17. The method according to claim 16, in which said symptoms are chosen from sleep and vigilance disorders.

18. The method according to claim 15 wherein the anti-parkinson drug is chosen from levodopa, ropinorole, lisuride, bromocriptine, pramixepole.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.